We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
News

Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin

Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
News

Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lonza and Agennix AG have announced an agreement for the production of Agennix’s first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC).

Under the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kouřim, Czech Republic.

This agreement initiates the process needed to be able to ultimately seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch.

“We are committed to supporting emerging therapeutics through clinical trial milestones,” said Dr. Stephan Kutzer, COO Lonza Custom Manufacturing.

Dr. Kutzer continued, “Our partnership with Agennix is an example of this commitment and demonstrates Lonza’s ability to offer access to our development and manufacturing expertise at an early stage of production.”

Rajesh Malik, M.D., Chief Medical Officer and Management Board member of Agennix, said: “We are pleased to enter this agreement with Lonza, which has extensive experience manufacturing biologics on a commercial scale. In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply.”

Advertisement